Impact of different endoscopic esophageal varices treatment on portal hypertensive gastropathy

Wei WU,Lifu WANG,Fenglai TAO,Beili XU,Peijun YE,Shu CHEN,Yaozong YUAN
DOI: https://doi.org/10.16150/j.1671-2870.2016.05.006
2016-01-01
Abstract:Objective: To analyze the impact of different endoscopic esophageal varices treatment on severity of portal hypertensive gastropathy (PHG). Methods: A total of 35 patients with endoscopic treatment of esophageal varices at Department of Gastroenterology, Shanghai Ruijin Hospital from January 2015 to March 2016 were enrolled. Either endoscopic injection sclerotherapy (EIS) or varices ligation (EVL) was performed, and the concomitant gastric varices, if present, was treated with tissue adhesive obturation (GVO). Additional endoscopic treatment was performed when necessary and patients were followed up for PHG evaluation. Results: Seventeen patients received EIS and 18 received EVL at the initial endoscopy. During follow-up, 16 and 13 patients of the above mentioned groups, respectively, remained in the same group, while the other 6 patients turned to receive a mixed therapy of EIS and EVL because of either technical failure, inadequate regression after EIS or residue varices not suitable for another EVL. Mean endoscopic follow-up was (8.6±4.0) months. Patients with severe, mild and absent of PHG were 0, 18, 17 at baseline and 3, 16, 16 at last follow-up, respectively (P>0.05). EVL and mixed therapy were seemed to be superior to EIS in both long-term hemostasis and PHG stability. The average Child-Pugh scores at baseline and last follow-up were (6.77± 1.73) and (6.00±0.91), respectively, indicating that endoscopic treatment was beneficial to liver function improvement (P<0.01). Conclusions: Endoscopic treatment for esophageal varices would not have significant negative influence on PHG.
What problem does this paper attempt to address?